|
1) Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137-48
|
|
|
|
2) Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature. 2001; 411: 380-4
|
|
|
|
|
|
3) Mocellin S, Rossi CR, Lise M, et al. Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology. 2004; 127: 1821-37
|
|
|
|
|
|
4) Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Annu Oncol. 2005; 16: 847-62
|
|
|
|
|
|
5) Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19: 145-66
|
|
|
|
|
|
6) Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007; 117: 1195-203
|
|
|
|
|
|
7) Bonifaz LC, Bonnyay DP, Charalambous A, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004; 199: 815-24
|
|
|
|
|
|
8) Smyth MJ, et al. A fresh look at tumor immunosurveillance and immunotherapy. Nat Rev Immunol. 2001; 2: 293-9
|
|
|
|
|
|
9) Tahara H, Shiozaki H, Kobayashi K, et al. Phenotypic characterisrics of tumor-infiltrating lymphocytes in human oesophageal cancer tissues defined by quantitative two-colour analysis with flow-cytometry. Virchows Archiv A Pathol Anat. 1990; 416: 329-34
|
|
|
|
|
|
10) Peges F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005; 353: 2654-66
|
|
|
|
|
|
11) Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313: 960-4
|
|
|
|
|
|
12) Rabinovich GA, Gabrilovich D, Sotomayor E. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25: 267-96
|
|
|
|
|
|
13) de Visser KE, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6: 24-37
|
|
|
|
|
|
14) Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441: 431-6
|
|
|
|
|
|
15) Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998; 188: 341-50
|
|
|
|
|
|
16) El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000; 404: 398-402
|
|
|
|
|
|
17) Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006; 442: 461-5
|
|
|
|
|
|
18) Pardal R, Clarke M, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003; 3: 895-902
|
|
|
|
|
|
19) Finn OJ, Fori G. Prophylactic cancer vaccines. Curr Opin Immunol. 2002; 14: 172-7
|
|
|
|
|
|
20) Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7: 41-51
|
|
|
|
|
|
21) Nishioka Y, Hirao M, Robbins PD, et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 1999; 59: 4035-41
|
|
|
|
|
|
22) Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Immunity. 2007; 12: 192-9
|
|
|
|
|